| 摘要 |
The present invention relates to an anticancer theranostic agent, capable of specifically targeting mitochondria. More specifically, the present invention relates to an anticancer theranostic agent, which comprises: a fluorescent source for in-situ monitoring cell necrosis with respect to drug activation; a tumor-targeting ingredient for specifically targeting tumor tissues; a drug precursor activation ingredient for activating a drug precursor; and a drug precursor converted to an active drug by the drug precursor activation ingredient. According to the present invention, provided is the theranostic agent, which exhibits excellent effects in inhibiting tumor growth, and is capable of self-monitoring cell necrosis of cancer cells during the activation and treating cancer in a precise manner. |
